U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C5H15N2O3PS.3H2O
Molecular Weight 268.269
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMIFOSTINE

SMILES

O.O.O.NCCCNCCSP(O)(O)=O

InChI

InChIKey=TXQPXJKRNHJWAX-UHFFFAOYSA-N
InChI=1S/C5H15N2O3PS.3H2O/c6-2-1-3-7-4-5-12-11(8,9)10;;;/h7H,1-6H2,(H2,8,9,10);3*1H2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C5H15N2O3PS
Molecular Weight 214.223
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/?term=17602063

Amifostine is an organic thiophosphate cytoprotective agent known chemically as 2-[(3¬ aminopropyl)amino]ethanethiol dihydrogen phosphate (ester), it’s adjuvant used in cancer chemotherapy and radiotherapy involving DNA-binding chemotherapeutic agents. It is marketed under the trade name Ethyol. Amifostine is a prodrug and is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically active free thiol metabolite. This metabolite is believed to be responsible for the reduction of the cumulative renal toxicity of cisplatin and for the reduction of the toxic effects of radiation on normal oral tissues. The ability of Ethyol to differentially protect normal tissues is attributed to the higher capillary alkaline phosphatase activity, higher pH and better vascularity of normal tissues relative to tumor tissue, which results in a more rapid generation of the active thiol metabolite as well as a higher rate constant for uptake into cells. The higher concentration of the thiol metabolite in normal tissues is available to bind to, and thereby detoxify, reactive metabolites of cisplatin. This thiol metabolite can also scavenge reactive oxygen species generated by exposure to either cisplatin or radiation. Healthy cells are preferentially protected because amifostine and metabolites are present in healthy cells at 100-fold greater concentrations than in tumor cells.

CNS Activity

Curator's Comment: Because amifostine does not cross the blood–brain barrier, the central nervous system, often the dose-limiting organ in radiotherapy, is not protected

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Secondary
ETHYOL

Approved Use

Amifostine for Injection is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. Amifostine for Injection is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands (see Clinical Studies ). For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin based chemotherapy regimens or radiation therapy is altered by Amifostine for Injection. There are at present only limited data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings. Amifostine should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, except in the context of a clinical study (see WARNINGS).

Launch Date

1995
Secondary
ETHYOL

Approved Use

Amifostine for Injection is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patient s with advanced ovarian cancer. Amifostine for Injection is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands (see Clinical Studies ). For the approved indications, the clinical data do not suggest that the effectiveness of cisplatin based chemotherapy regimens or radiation therapy is altered by Amifostine for Injection. There are at present only limited data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings. Amifostine should not be administered to patients in other settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, except in the context of a clinical study (see WARNINGS).

Launch Date

1995
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 min
910 mg/m² 1 times / day other, intravenous
dose: 910 mg/m²
route of administration: Intravenous
experiment type: OTHER
co-administered:
AMIFOSTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
200 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / day
Co-administed with::
radiation treatment
Sources: Page: 9
unhealthy, adult
n = 150
Health Status: unhealthy
Condition: Head and Neck Cancer
Age Group: adult
Sex: unknown
Population Size: 150
Sources: Page: 9
Other AEs: Nausea and vomiting, Nausea and vomiting...
Other AEs:
Nausea and vomiting (grade 3-4, 8%)
Nausea and vomiting (all grades, 53%)
Hypotension (grade 3-4, 3%)
Hypotension (all grades, 15%)
Sources: Page: 9
910 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 910 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 910 mg/m2, 1 times / day
Co-administed with::
cisplatin(100 mg/m2)
Sources: Page: 9
unhealthy, adult
n = 122
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: adult
Sex: unknown
Population Size: 122
Sources: Page: 9
Disc. AE: Blood pressure decreased...
Other AEs: Nausea and vomiting, Nausea and vomiting...
AEs leading to
discontinuation/dose reduction:
Blood pressure decreased (<3%)
Other AEs:
Nausea and vomiting (grade 3-4, 30%)
Nausea and vomiting (all grades, 96%)
Hypotension (grade 3-4, 8%)
Hypotension (all grades, 61%)
Sources: Page: 9
AEs

AEs

AESignificanceDosePopulation
Hypotension all grades, 15%
200 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / day
Co-administed with::
radiation treatment
Sources: Page: 9
unhealthy, adult
n = 150
Health Status: unhealthy
Condition: Head and Neck Cancer
Age Group: adult
Sex: unknown
Population Size: 150
Sources: Page: 9
Nausea and vomiting all grades, 53%
200 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / day
Co-administed with::
radiation treatment
Sources: Page: 9
unhealthy, adult
n = 150
Health Status: unhealthy
Condition: Head and Neck Cancer
Age Group: adult
Sex: unknown
Population Size: 150
Sources: Page: 9
Hypotension grade 3-4, 3%
200 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / day
Co-administed with::
radiation treatment
Sources: Page: 9
unhealthy, adult
n = 150
Health Status: unhealthy
Condition: Head and Neck Cancer
Age Group: adult
Sex: unknown
Population Size: 150
Sources: Page: 9
Nausea and vomiting grade 3-4, 8%
200 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 200 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg/m2, 1 times / day
Co-administed with::
radiation treatment
Sources: Page: 9
unhealthy, adult
n = 150
Health Status: unhealthy
Condition: Head and Neck Cancer
Age Group: adult
Sex: unknown
Population Size: 150
Sources: Page: 9
Blood pressure decreased <3%
Disc. AE
910 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 910 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 910 mg/m2, 1 times / day
Co-administed with::
cisplatin(100 mg/m2)
Sources: Page: 9
unhealthy, adult
n = 122
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: adult
Sex: unknown
Population Size: 122
Sources: Page: 9
Hypotension all grades, 61%
910 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 910 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 910 mg/m2, 1 times / day
Co-administed with::
cisplatin(100 mg/m2)
Sources: Page: 9
unhealthy, adult
n = 122
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: adult
Sex: unknown
Population Size: 122
Sources: Page: 9
Nausea and vomiting all grades, 96%
910 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 910 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 910 mg/m2, 1 times / day
Co-administed with::
cisplatin(100 mg/m2)
Sources: Page: 9
unhealthy, adult
n = 122
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: adult
Sex: unknown
Population Size: 122
Sources: Page: 9
Nausea and vomiting grade 3-4, 30%
910 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 910 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 910 mg/m2, 1 times / day
Co-administed with::
cisplatin(100 mg/m2)
Sources: Page: 9
unhealthy, adult
n = 122
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: adult
Sex: unknown
Population Size: 122
Sources: Page: 9
Hypotension grade 3-4, 8%
910 mg/m2 1 times / day multiple, intravenous
Recommended
Dose: 910 mg/m2, 1 times / day
Route: intravenous
Route: multiple
Dose: 910 mg/m2, 1 times / day
Co-administed with::
cisplatin(100 mg/m2)
Sources: Page: 9
unhealthy, adult
n = 122
Health Status: unhealthy
Condition: Ovarian Cancer
Age Group: adult
Sex: unknown
Population Size: 122
Sources: Page: 9
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as victim

Drug as victim

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-kappaB/Rel transcription factors.
1999 Dec 15
The potential of amifostine: from cytoprotectant to therapeutic agent.
1999 Nov
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
2000
Systemic inflammatory response syndrome associated with amifostine.
2000 Apr
Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cellautotransplant: a retrospective study.
2000 Aug
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
2000 Aug
Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
2000 Dec
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
2000 Jan
Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: a multicenter phase II study.
2000 Jun
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
2000 Mar 1
Immunocytochemical analysis of apoptotic bone marrow cells after treatment of mice with WR-2721 and chemotherapeutic drugs.
2001
Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
2001
High remission rate in acute myeloblastic leukemia with only two days of chemotherapy.
2001 Apr
[Comments on five clinical trials concerning radiotherapy-induced mucositis in patients with head and neck neoplasms].
2001 Apr
T-cell apoptosis induced by granulocyte colony-stimulating factor is associated with retinoblastoma protein phosphorylation and reduced expression of cyclin-dependent kinase inhibitors.
2001 Apr
Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor.
2001 Aug
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
2001 Aug
Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide.
2001 Aug
PBPC mobilization with paclitaxel, ifosfamide, and G-CSF with or without amifostine: results of a prospective randomized trial.
2001 Feb
Effect of amifostine on toxicities associated with salvage combination chemotherapy.
2001 Feb
Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds.
2001 Feb
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
2001 Feb 2
Anticancer drug-induced kidney disorders.
2001 Jan
A randomized trial of amifostine as a cytoprotective agent in patients receiving chemotherapy for small cell lung cancer.
2001 Jan 5
Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide.
2001 Jun
Effect of amifostine on lipid peroxidation caused by cisplatin in rat kidney.
2001 Jun
Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs.
2001 Jun
Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay.
2001 Jun 14
Activation of NFkappaB and MnSOD gene expression by free radical scavengers in human microvascular endothelial cells.
2001 Jun 15
Prophylactic efficacy of amifostine and its analogues against sulphur mustard toxicity.
2001 Jun 21
Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
2001 Mar
In vivo effects of IL-4, IL-10, and amifostine on cytokine production in patients with acute myelogenous leukemia.
2001 Mar
Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.
2001 Mar
Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
2001 Mar
Effects of retinoic acid and amifostine on in vitro growth of normal hemopoietic progenitor cells.
2001 Mar-Apr
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
2001 Nov 15
Alteration of radiation-induced hematotoxicity by amifostine.
2001 Nov 15
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
2001 Nov 15
Sensitizers and protectors of radiation and chemotherapy.
2001 Nov-Dec
The role of amifostine as a radioprotector.
2001 Oct
Protective effects of amifostine and its analogues on sulfur mustard toxicity in vitro and in vivo.
2001 Oct 1
Poor prognosis acute myelogenous leukemia: 3--biological and molecular biological changes during remission induction therapy.
2001 Sep
Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
2001 Sep 1
New dosing regimens for amifostine: a pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion.
2002 Feb
Flow cytometric estimation of the plasma membrane diversity of bone marrow cells in mice treated with WR-2721 and cyclophosphamide.
2002 Feb 28
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
2002 Jan
Esophageal cancer and the esophagus: challenges and potential strategies for selective cytoprotection of the tumor-bearing organ during cancer treatment.
2002 Jan
Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
2002 Jan
Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
2002 Mar
Patents

Patents

Sample Use Guides

For Reduction of Cumulative Renal Toxicity with Chemotherapy: The recommended starting dose is 910 mg/m2 administered once daily as a 15-minute infusion. For Reduction of Moderate to Severe Xerostomia from Radiation of the Head and Neck: The recommended dose is 200 mg/m2 administered once daily as a 3-minute infusion starting 15-30 minutes prior to standard fraction radiation therapy (1.8-2.0 Gy). infusion, starting 30 minutes prior to chemotherapy.
Route of Administration: Intravenous
Human pulmonary EC were grown on golden microelectrodes. Cells were pretreated with WR-1065 (unprotected form of amifostine, used for cell culture treatments) (0.4 mM, 1 mM or 4 mM, 30 min) followed by stimulation with 250 mM H2O2 (Panel A). EC were pretreated with 4 mM
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:20:29 GMT 2023
Edited
by admin
on Fri Dec 15 16:20:29 GMT 2023
Record UNII
M487QF2F4V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMIFOSTINE
MART.   ORANGE BOOK   USAN   USP   VANDF  
USAN  
Official Name English
AMIFOSTINE [MART.]
Common Name English
AMIFOSTINE [USP MONOGRAPH]
Common Name English
GAMMAPHOS
Common Name English
Amifostine trihydrate [WHO-DD]
Common Name English
AMIFOSTINE [USP-RS]
Common Name English
WR-2721 TRIHYDRATE
Code English
AMIFOSTINE [USAN]
Common Name English
S-[2-[(3-Aminopropyl)amino]ethyl] dihydrogen phosphorothioate, trihydrate
Systematic Name English
NSC-296961
Code English
AMIFOSTINE [VANDF]
Common Name English
AMIFOSTINE TRIHYDRATE [MI]
Common Name English
ETHYOL
Brand Name English
AMIFOSTINE TRIHYDRATE
MI   WHO-DD  
Common Name English
ETHIOFOS
Common Name English
ETHANETHIOL, 2-((3-AMINOPROPYL)AMINO)-, DIHYDROGEN PHOSPHATE (ESTER), TRIHYDRATE
Common Name English
AMIFOSTINE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 128399
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
FDA ORPHAN DRUG 116298
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
WHO-VATC QV03AF05
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
FDA ORPHAN DRUG 24187
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
FDA ORPHAN DRUG 42989
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
FDA ORPHAN DRUG 111698
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
NDF-RT N0000180854
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
FDA ORPHAN DRUG 42789
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
NCI_THESAURUS C2080
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
FDA ORPHAN DRUG 42889
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
LIVERTOX 36
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
WHO-ATC V03AF05
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
Code System Code Type Description
MESH
D004999
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
USAN
DD-7
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
DRUG BANK
DB01143
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
RXCUI
4126
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY RxNorm
DAILYMED
M487QF2F4V
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
WIKIPEDIA
AMIFOSTINE
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
RS_ITEM_NUM
1019406
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
MERCK INDEX
m1669
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY Merck Index
SMS_ID
100000091456
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
NCI_THESAURUS
C488
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
EPA CompTox
DTXSID40150210
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
EVMPD
SUB27016
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
CHEBI
2636
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
FDA UNII
M487QF2F4V
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
ChEMBL
CHEMBL1006
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
CAS
112901-68-5
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
NSC
296961
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
DRUG CENTRAL
156
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
PUBCHEM
148139
Created by admin on Fri Dec 15 16:20:29 GMT 2023 , Edited by admin on Fri Dec 15 16:20:29 GMT 2023
PRIMARY
Related Record Type Details
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC